MarketResearchNest.com adds “Grass Pollen Allergy – Pipeline Review, H2 2017” new report to its research database. The report spread across in 43 pages with table and figures in it.
Latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy – Pipeline Review, H2 2017, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.
Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies.
Enquiry for buying at: https://www.marketresearchnest.com/enquirybuy.php?reportid=254871
The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 3 and 2 respectively.
Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this report includes:
ALK-Abello A/S, Allergy Therapeutics Plc, Biomay AG, HAL Allergy BV
Order a Premium Purchase Report Copy at : https://www.marketresearchnest.com/purchase.php?reportid=254871
Featured News & Press Releases
Jan 26, 2017: Biomay AG Reports Positive Results From A Second Phase IIb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32
Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B
Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204
Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children
Mar 04, 2016: Inflamax Research Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC) Study
Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL
Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32
Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children
Jun 03, 2015: Positive phase IIb data on BM32, Biomay’s innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference.
Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32
Apr 14, 2014: ALK announces FDA approval for Merck’s grass sublingual allergy immunotherapy tablet GRASTEK
Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study
Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32
Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK
Reasons to buy:
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquiry for Discount at: https://www.marketresearchnest.com/requestdiscount.php?reportid=254871
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain